Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение дефицита тестостерона (гипогонадизма) у мужчин

Список литературы [REFERENCES]

  1. Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин. Проект. // Проблемы эндокринологии, 2015 - №5.- 61(5):60-71
  2. Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин. // Проблемы эндокринологии, 2016 - №6.- 62(6):78-80.
  3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 8- й выпуск. – М.: УП ПРИНТ; 2017. ISBN 978-5-91487-090-1 DOI: 10.14341/DM20171S8
  4. Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. The Aging Male. 2015;14(1):10-15. doi: 10.3109/13685538.2010.511325.
  5. Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and metaanalysis of randomized controlled trials. Asian J Androl 2013 Dec 16. doi: 10.4103/1008-682X.122346.
  6. Ding E.L., Song Y., Mafk V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic Review and Meta-analysis // JAMA, 2006.- Vol.295 (11).-p.1288-99.
  7. Endocrine Society. "Previously Unrecognized Testosterone Deficiency Common In Men With Type 1 Diabetes." ScienceDaily. ScienceDaily, 27 March 2008. <www.sciencedaily.com/releases/2008/03/080326202018.htm>.
  8. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2010;95(6):2536-2559. doi: 10.1210/jc.2009-2354.
  9. Agarwal PK, Singh P, Chowdhury S, Sharma SK, Majumdar A, Shah P, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus // Indian J Endocr Metab 2017;21:64-70. DOI: 10.4103/2230-8210.196008.
  10. Beatrice A, Dutta D, Kumar M, Siddegowda K, Sinha S, Ray S, Chowdhury S. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications // Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 481–486. DOI https://doi.org/10.2147/DMSO.S50777).
  11. EAU Guidelines. Edn. presented at the EAU Annual Congress London 2017. ISBN 978-90-79754-91-5.
  12. Rosner W, Vesper H. Toward Excellence in Testosterone Testing: A Consensus Statement. J Clin Endocr Metab. 2010;95(10):4542-4548. doi: 10.1210/jc.2010-1314.
  13. Bhasin S, Pencina M, Jasuja GK, et al. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community- Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocr Metab. 2011;96(8):2430-2439. doi: 10.1210/jc.2010-3012.
  14. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: 10.1056/NEJMoa0911101.
  15. Lejeune H, Huyghe É, Droupy S. Diminution du désir sexuel et déficit en testostérone chez l’homme. Prog Urol. 2013;23(9):621-628. doi: 10.1016/j.purol.2013.01.019.
  16. Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. The Aging Male. 2015;15(4):187-197. doi: 10.3109/13685538.2012.729110.
  17. Ho CH, Jaw FS, Wu CC, Chen KC, Wang CY, Hsieh JT, Yu HJ, Liu SP. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men // J Sex Med. 2015 Feb;12(2):389-97. doi: 10.1111/jsm.12777.
  18. Курбатов Д.Г., Дубский С.А., Роживанов Р.В., Лепетухин А.Е., Шварц Я.Г. Урологические и андрологические заболевания при сахарном диабете / в кн. Сахарный диабет и репродуктивная система // под ред. академика РАН Дедова И. И., члена-корреспондента РАН Шестаковой М. В. – М.: ООО Издательство «Медицинское информационное агентство».-2016.-С. 135- 148.
  19. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. doi: 10.3275/8061.
  20. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology. 2011;166(1):77-85. doi: 10.1530/eje-11-0743.
  21. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). The Aging Male. 2015;15(1):14-21. doi: 10.3109/13685538.2011.606513.
  22. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010;341(aug31 1):c4462-c4462. doi: 10.1136/bmj.c4462.
  23. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice & Research Clinical Endocrinology & Metabolism. 2011;25(2):221-238. doi: 10.1016/j.beem.2010.08.013.
  24. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3 Suppl):14-22.
  25. Vermeulen A, Verdonck L, Kaufman JM. A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum. J Clin Endocr Metab. 1999;84(10):3666- 3672. doi: 10.1210/jcem.84.10.6079.
  26. Tajar A, McBeth J, Lee DM, et al. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain. 2011;152(7):1495-1501. doi: 10.1016/j.pain.2011.01.048.
  27. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010 Apr; 95(4):1810-8.
  28. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3 Suppl):28-31.
  29. Bremner AP, Feddema P, Leedman PJ, et al. Age-Related Changes in Thyroid Function: A Longitudinal Study of a Community-Based Cohort. J Clin Endocr Metab. 2012;97(5):1554-1562. doi: 10.1210/jc.2011-3020.
  30. Rastrelli G., Corona G., Tarocchi M., Mannucci E., Maggi M. How to define hypogonadism? Result from a population of men consulting for sexual dysfunction // J Endocrinol Invest. 2016; 39(4):473-484.
  31. Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocr Metab. 2006;91(11):4335- 4343. doi: 10.1210/jc.2006-0401.
  32. Tan WS, Ng CJ, Khoo EM, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male 2011;14:231–6.
  33. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low Testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology 2013;82:814–19.
  34. Antonio L, Wu FCW, O’Neill TW, et al. Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men // J Clin Endocrinol Metab. 2015;100(4):1396-1404. doi: 10.1210/jc.2014-4184.
  35. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–17.
  36. Tajar A, Huhtaniemi IT, O’Neill TW, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;97:1508–16.
  37. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, Corona G, Onat A, Maggio M, Bouchard C, Tong PC, Chen RY, Akishita M, Gietema JA, Gannagé-Yared MH, Undén AL, Hautanen A, Goncharov NP, Kumanov P, Chubb SA, Almeida OP, Wittchen HU, Klotsche J, Wallaschofski H, Völzke H, Kauhanen J, Salonen JT, Ferrucci L, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta- analysis of observational studies. // PLoS One. 2014; 9(7):e100409.
  38. Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. Journal of Diabetes Investigation. 2015; 6(2):112-123. doi: 10.1111/jdi.12288.
  39. Fukui M., Kitagawa Y., Nakamura N. et al Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes.// Diabetes Care.- 2003.-Vol. 26.-P.1869–1873.
  40. Kloner R.A., Mullin S.H., Shook T., et al. Erectile dysfunction in the cardiac patient: how common and should we treat? // J Urol.- 2003.- Vol.170, N.2. Pt 2.-S.46-50.
  41. Sullivan M.E., Thompson C.S., Dashwood M.R., Khan M.A., Jeremy J.Y., Morgan R.J. et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular diseae? // Cardiovasc Res.- 1999.-Vol. 43,N.3.-P.658-665.
  42. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. // Eur Urol.- 2003.-Vol.44, N.3.-P.360-364.
  43. Muraleedharan V., Marsh H., Kapoor D., Channer K.S., Jones T.H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. // Eur. J. Endocrinol, 2013;169(6):725- 33. doi:10.1530/EJE-13-0321.
  44. Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins // Int J Clin Pract. 2016 Mar; 70(3):244-53. doi: 10.1111/ijcp.12779.
  45. Роживанов Р.В., Шурдумова Б.О., Парфенова Н.С., Савельева Л.В. Комплексный подход к лечению ожирения и метаболического синдрома у мужчин. // Ожирение и метаболизм. - 2009. – Т. 6. - №4 – С. 38-41. [Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel'eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (in Russ.)] doi: 10.14341/2071-8713-4877.
  46. Роживанов Р.В. Эффективная терапия и ошибки в лечении эндокринных нарушений в андрологии / в кн. Эндокринология. Фармакотерапия без ошибок // под ред. академика РАН и РАМН Дедова И.И., академика РАМН Мельниченко Г. А. Москва, 2013.- с. 615-625. [Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA, (eds.). Endocrinology. Pharmacotherapy without errors. Moscow; 2013. P. 615-625. (in Russ.)]
  47. Pechersky A. Features of diagnostics and treatment of partial androgen deficiency of aging men. Cent European J Urol. 2014;67:397-404. doi: 10.5173/ceju.2014.04.art16.
  48. Роживанов Р.В. Эндокринные нарушения половой функции у мужчин / В кн. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ. / под ред. академика РАН и РАМН Дедова И.И., академика РАМН Мельниченко Г.А. Второе издание, исправленное и дополненное. - Москва, 2013.- с. 754-775. [Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel’nochenko GA, (eds.). Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. Moscow; 2013. s. 754-775. (in Russ.)]
  49. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement // BJU Int. 2016 Apr;117(4):677-85. doi: 10.1111/bju.13337.
  50. Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi: 10.1111/j.1743-6109.2010.01765.x.
  51. Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: 10.2147/cia.s4466.
  52. Lunenfeld B., Mskhalaya G., Zitzmann M., Arver S., Kalinchenko S., Tishova Y., Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men // Aging Male, 2015 Early Online: 1–11 DOI: 10.3109/13685538.2015.1004049.
  53. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: 10.1007/s10549-005-9074-y.
  54. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: 10.1210/jc.2009-2575.
  55. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi: 10.1530/eje-11-0221.
  56. Pearl JA, Berhanu D, Francois N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828-1833. doi: 10.1016/j.juro.2013.05.111.
  57. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: 10.1517/14740338.2014.950653.
  58. Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(11):1451-1457. doi: 10.1093/gerona/60.11.1451.
  59. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. doi: 10.1056/NEJMoa1000485.
  60. Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. 2007;4(5):1241-1246. doi: 10.1111/j.1743-6109.2007.00553.x.
  61. Saad F, Gooren L, Haider A, Yassin A. An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome. Syst Biol Reprod Med. 2007;53(6):353-357. doi: 10.1080/01485010701730880.
  62. Haider A, Gooren LJG, Padungtod P, Saad F. Improvement of the Metabolic Syndrome and of Non-alcoholic Liver Steatosis upon Treatment of Hypogonadal Elderly Men with Parenteral Testosterone Undecanoate. Exp Clin Endocrinol Diabetes. 2009;118(03):167-171. doi: 10.1055/s-0029-1202774.
  63. Haider A, Saad F, Doros G, Gooren L Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study // Obes Res Clin Pract. 2014 Jul-Aug; 8(4):e339-49. doi: 10.1016/j.orcp.2013.10.005.
  64. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975–81.
  65. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obesity 2013;3:73–83.
  66. Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167–74.
  67. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: a meta-analysis study // Int J Androl. 2011 Dec;34(6 Pt 1):528-40. doi: 10.1111/j.1365-2605.2010.01117.x.
  68. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515. doi: 10.1155/2014/683515.
  69. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. doi: 10.1530/eje.1.02166.
  70. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late onset hypogonadism and metabolic syndrome: results from a 24-months, randomized double blind placebo-controlled study. J Sex Med 2010;7:3495–503.
  71. Strollo F, Strollo G, More M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male 2013;16:33–7.
  72. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726–33.
  73. Hackett G, Cole N, Bhartia M, et al. Blast Study Group. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68:203–15.
  74. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care, 2011, 34(4):828-37.
  75. Wallis CJ, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, Herschorn S, Kodama RT, Cheung P, Narod SA, Nam RK. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016 Jun;4(6):498-506. doi: 10.1016/S2213- 8587(16)00112-1. Epub 2016 May 7. PMID: 27165609.
  76. Moon du G, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido((R))) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7(6):2253-2260. doi: 10.1111/j.1743- 6109.2010.01765.x.
  77. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572-2582. doi: 10.1111/j.1743-6109.2010.01859.x.
  78. Aversa A, Francomano D, Lenzi A. Does testosterone supplementation increase PDE5- inhibitor responses in difficult-to-treat erectile dysfunction patients? Expert Opin Pharmacother. 2015 Apr;16(5):625-8. doi: 10.1517/14656566.2015.1011124. Epub 2015 Feb 3.
  79. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10(2):579-588. doi: 10.1111/j.1743-6109.2012.02853.x.
  80. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: 10.1111/j.1365-2141.2005.05535.x.
  81. Роживанов Р.В., Курбатов Д.Г. Гематологические и урологические аспекты безопасности заместительной андрогенной терапии препаратом тестостерона ундеканоата пролонгированного действия у пациентов с гипогонадизмом // Проблемы эндокринологии. - 2009. - № 6, том 55.- с. 31-35.
  82. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482-492. doi: 10.1056/NEJMra022251.
  83. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother. 2014;48(9):1138-1144. doi: 10.1177/1060028014539918.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы [REFERENCES]
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*